Valuation: Clene Inc.

Market Cap 80.12M 70.39M 65.27M 60.02M 113M 7.66B 116M 778M 304M 3.76B 301M 294M 13.01B P/E 2026 *
-3.51x
P/E 2027 * -4.26x
Enterprise Value 66.72M 58.62M 54.35M 49.98M 94.43M 6.38B 96.45M 648M 253M 3.13B 251M 245M 10.84B EV / Sales 2026 *
322x
EV / Sales 2027 * 2.48x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+1.91%
1 week+4.75%
Current month+3.82%
1 month+9.42%
3 months+4.58%
6 months+23.36%
Current year+8.86%
1 week 5.83
Extreme 5.83
6.39
1 month 5.5
Extreme 5.5
6.46
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
17
5 years 2.28
Extreme 2.2801
273.87
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
11/06Free

Founder

45,000 0.3522%
11/06Free

Chief Financial Officer

15,000 0.1174%
11/06Free

Chief Executive Officer

65,000 0.5087%
Change 5-day change 1-year change 3-year change Capi.($)
+1.91%+4.75%+77.99%-60.34% 80.12M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-8.57%+58.09%+124.47% 54.63B
-5.60%-2.20%+11.16%+437.37% 25.06B
-1.55%-7.66%-20.21%-17.37% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+1.87%+38.13%-26.14% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-0.81%+0.34%+24.92%+189.31% 14.2B
Average -1.40%-0.46%+52.13%+172.42% 24.17B
Weighted average by Cap. -1.81%-1.56%+48.51%+166.82%

Financials

2026 *2027 *
Net sales 207K 182K 169K 155K 294K 19.83M 300K 2.01M 788K 9.74M 779K 762K 33.69M 23.64M 20.77M 19.26M 17.71M 33.46M 2.26B 34.18M 230M 89.82M 1.11B 88.78M 86.84M 3.84B
Net income -25.09M -22.05M -20.44M -18.8M -35.51M -2.4B -36.28M -244M -95.33M -1.18B -94.22M -92.16M -4.08B -27.55M -24.2M -22.44M -20.64M -38.99M -2.63B -39.82M -268M -105M -1.29B -103M -101M -4.47B
Net Debt -13.4M -11.77M -10.92M -10.04M -18.96M -1.28B -19.37M -130M -50.9M -629M -50.31M -49.22M -2.18B -21.4M -18.8M -17.43M -16.03M -30.29M -2.05B -30.94M -208M -81.29M -1.01B -80.35M -78.6M -3.48B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
13/07/26 USD 6.390 +1.91% 72,446
10/07/26 USD 6.270 +0.32% 33,705
09/07/26 USD 6.250 +2.80% 50,244
08/07/26 USD 6.080 -0.65% 41,043
07/07/26 USD 6.120 +1.83% 71,775
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.390USD
Average target price
32.20USD
Spread / Average Target
+403.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock